Alzheimer Disease: Clinical and Biological Heterogeneity
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
The clinical and biological features of Alzheimer disease are not uniform in their expression; heterogeneity is evident in the disease's clinical, anatomic, and physiologic characteristics. The presence of considerable intersubject and intrasubject heterogeneity suggests that subtypes of the disease exist. We define subtypes of Alzheimer disease in regard to the behavioral features (for example, predominant right or left hemisphere, or symmetrical impairment), inheritance (familial or sporadic), dosage of chromosome 21 (presence of the Down syndrome), time course of progression, age of onset (presenile or senile), and presence or absence of motor deficit (myoclonus or signs of an extrapyramidal syndrome). Studies of regional cerebral glucose metabolism with positron emission tomography and [18-fluorine] fluorodeoxyglucose show focal alterations in glucose use, with cerebral metabolic asymmetries in patients with Alzheimer disease that are related to the nature of the cognitive deficit. Serial roentgenographic computed tomographic studies show heterogeneous rates of lateral ventricle enlargement in the disease that are related to rates of cognitive decline. Similar anatomic and physiologic abnormalities are also found in persons 45 years of age or older who have the Down syndrome. Furthermore, patients with Alzheimer disease who have extrapyramidal dysfunction or myoclonus are a distinct subgroup, with specific abnormalities of central monoamine markers of dopamine metabolism, serotonin metabolism, and the hydroxylation cofactor, biopterin. The concept of subtypes in Alzheimer disease serves as a model with which the interactions of genetic influences with environmental factors can be examined.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sokoloff, L., Reivich, M., Kennedy, C., Rosiers, M. H. D., Patlak, C. S., Pettigrew, K. D., Sakurada, O., & Shinohara, M. (1977) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1977.tb10649.x · Cited by 6,000
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
Alzheimer's disease: cell-specific pathology isolates the hippocampal formation.
Hyman, B. T., Van Hoesen, G. W., Damasio, A. R., & Barnes, C. L. (1984) · Science · doi:10.1126/science.6474172 · Cited by 2,268
Alzheimer's disease and Down's syndrome: Sharing of a unique cerebrovascular amyloid fibril protein
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(84)91209-9 · Cited by 1,693
Amyloid β Protein Gene: cDNA, mRNA Distribution, and Genetic Linkage Near the Alzheimer Locus
Tanzi, R. E., Gusella, J. F., Watkins, P. C., Bruns, G. A. P., St George-Hyslop, P., Van Keuren, M. L., Patterson, D., Pagan, S., Kurnit, D. M., & Neve, R. L. (1987) · Science · doi:10.1126/science.2949367 · Cited by 1,611
Occurrence of neuropathological changes and dementia of Alzheimer’s disease in Down’s syndrome
Wisniewski, K. E., Wisniewski, H. M., & Wen, G. Y. (1985) · Annals of Neurology · doi:10.1002/ana.410170310 · Cited by 1,159
Pearson, R. C., Esiri, M. M., Hiorns, R. W., Wilcock, G. K., & Powell, T. P. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.13.4531 · Cited by 987
Seizures and myoclonus in patients with Alzheimer's disease
Hauser, W. A., Morris, M. L., Heston, L. L., & Anderson, V. E. (1986) · Neurology · doi:10.1212/wnl.36.9.1226 · Cited by 336
Burns, R. S., LeWitt, P. A., Ebert, M. H., Pakkenberg, H., & Kopin, I. J. (1985) · New England Journal of Medicine · doi:10.1056/nejm198505303122203 · Cited by 244
Cited by
Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges
Williams, D. R., & Lees, A. J. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70042-0 · Cited by 650
Screening for Alzheimer's Disease by Clock Drawing
Wolf‐Klein, G. P., Silverstone, F. A., Levy, A. P., Brod, M. S., & Breuer, J. (1989) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1989.tb02234.x · Cited by 407
Clinical, imaging, and pathological heterogeneity of the Alzheimer's disease syndrome
Lam, B., Masellis, M., Freedman, M., Stuss, D. T., & Black, S. E. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt155 · Cited by 386
Cognitive stimulation of patients with dementia: Preliminary results
Breuil, V., De Rotrou, J., Forette, F., Tortrat, D., Ganansia‐Ganem, A., Frambourt, A., Moulin, F., & Boller, F. (1994) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.930090306 · Cited by 209
Heterogeneity of Alzheimer’s disease: consequence for drug trials?
Devi, G., & Scheltens, P. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0455-y · Cited by 102
Metadata
- Authors
- Friedland, R. P., Koss, E., Haxby, J. V., Grady, C. L., Luxenberg, J., Schapiro, M. B., & Kaye, J.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 1988-08-15
- Volume
- 109
- Issue
- 4
- Pages
- 298-311
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2035052943
- Cited by
- 101
- References
- 9
- FWCI
- 8.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Alzheimer Disease: Clinical and Biological Heterogeneity. https://app.cochat.ai/papers/10.7326/0003-4819-109-4-298
- The paper
- Friedland, R. P., Koss, E., Haxby, J. V., Grady, C. L., Luxenberg, J., Schapiro, M. B., & Kaye, J. (1988). Alzheimer Disease: Clinical and Biological Heterogeneity. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-109-4-298
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.